PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
22.78%
Cost growth less than half of TRVN's 996.30%. David Dodd would verify if cost advantage is structural.
-30.37%
Both companies show declining gross profit. Martin Whitman would check industry conditions.
-30.37%
Margin decline while TRVN shows 0.00% expansion. Joel Greenblatt would examine competitive position.
45.24%
R&D growth above 1.5x TRVN's 22.72%. Michael Burry would check for spending discipline.
-4.95%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
24.69%
Operating expenses growth while TRVN reduces costs. John Neff would investigate differences.
24.69%
Total costs growth above 1.5x TRVN's 3.40%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
22.78%
D&A growth while TRVN reduces D&A. John Neff would investigate differences.
-24.88%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
-24.88%
EBITDA margin decline while TRVN shows 0.00% growth. Joel Greenblatt would examine position.
-24.83%
Both companies show declining income. Martin Whitman would check industry conditions.
-24.83%
Operating margin decline while TRVN shows 0.00% growth. Joel Greenblatt would examine position.
291.57%
Similar other expenses growth to TRVN's 373.81%. Walter Schloss would investigate industry patterns.
-21.98%
Both companies show declining income. Martin Whitman would check industry conditions.
-21.98%
Pre-tax margin decline while TRVN shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-17.79%
Net income decline while TRVN shows 0.97% growth. Joel Greenblatt would examine position.
-17.79%
Net margin decline while TRVN shows 0.00% growth. Joel Greenblatt would examine position.
-12.12%
EPS decline while TRVN shows 3.98% growth. Joel Greenblatt would examine position.
-9.09%
Diluted EPS decline while TRVN shows 3.98% growth. Joel Greenblatt would examine position.
5.06%
Share count reduction below 50% of TRVN's 3.14%. Michael Burry would check for concerns.
6.04%
Diluted share reduction below 50% of TRVN's 3.14%. Michael Burry would check for concerns.